A three-engine bet on Western supply-chain re-shoring—AI/quantum silicon, HALEU nuclear fuels, and scarce helium—where execution speed determines whether ASPI becomes indispensable or dilutive.
Overview
ASP Isotopes (ASPI) is a 2021-founded advanced materials and deep-tech company focused on commercial-scale enrichment of specialized isotopes at the intersection of supply-chain security, next-gen semiconductors (AI/quantum), and a nuclear power resurgence. It has rapidly moved from R&D into early commercialization, building and commissioning three enrichment facilities in Pretoria, South Africa, and beginning global shipments, while maintaining U.S. headquarters presence (Washington, D.C.) and establishing QLE’s base in Austin, Texas. ASPI’s moat centers on two proprietary separation technologies: the Aerodynamic Separation Process (ASP), particularly effective for light isotopes in volatile gas form (a category where centrifuges are less efficient), and Quantum Enrichment (QE), a laser-based approach in development for heavier elements aimed at nuclear fuel applications. The business is organized into three pillars: (1) Specialist Isotopes (Si-28, C-14, Mo-100, Yb-176), targeting semiconductor, quantum computing, pharma/agrochemical tracing, and radiopharma demand, with long-term take-or-pay contracts and first Si-28/Yb-176 commercial samples shipped Aug 2025; (2) Nuclear Fuels via wholly owned Quantum Leap Energy (QLE), pre-revenue but positioned around HALEU/LEU+ needs for SMRs and U.S. policy shifts; and (3) Helium/LNG via the acquisition of Renergen (closed Jan 2026), providing nearer-term offtake-backed cash flow and critical-mineral exposure in a tight global helium market.